When people encounter Peptide Therapy research for the first time, it can seem like a recent development, especially with the new “boom” online. 

The history of peptides in scientific research stretches back well over a century, with roots in some of the most significant discoveries in the entire history of medicine.

Peptide signalling is not as recent a concept as it may seem. It is one of the most fundamental mechanisms through which the human body communicates at a cellular level, and scientists have been studying it since the earliest years of the twentieth century. 

Understanding where peptide science came from helps to explain why the field is where it is today, and why the compounds being researched now are built on such a deep scientific foundation.

What Are Peptides And Why Should You Care?

A peptide is a short chain of amino acids, the same building blocks that make up proteins. 

The distinction between a peptide and a protein is largely one of length: peptides are generally shorter, typically fewer than fifty amino acids, while proteins are longer and more structurally complex. 

This relative simplicity is part of what makes peptides scientifically interesting.

The body produces thousands of peptides naturally and many of them function as signalling molecules, carrying instructions between cells, tissues, and organ systems. 

Many hormones, growth factors, neuropeptides and immune mediators are peptides or contain peptide components.

When researchers study the history of peptides, they are tracing the history of one of the body’s most fundamental communication systems.

The Early Discoveries: 1900s to 1950s

The scientific story of peptides begins in 1902, when British physiologists William Bayliss and Ernest Starling identified secretin, a compound released by the small intestine that signals the pancreas to produce bicarbonate-rich digestive fluid.

This discovery introduced a new concept to science: that the body uses chemical messengers travelling through the bloodstream to coordinate biological processes between distant organs. 

The term hormone was coined shortly after, by Starling in 1905, and the discovery became one of the foundational events in the development of endocrinology (the study of hormones and their effects).

Two decades later, in 1921, Frederick Banting and Charles Best produced pancreatic extracts that lowered blood glucose in animals at the University of Toronto.

However, the wider development of insulin should also recognise physiologist J. J. R. Macleod, who provided the laboratory and scientific support, and biochemist James Collip, whose purification work helped produce an extract suitable for successful clinical treatment.

Insulin is a peptide hormone, and its isolation marked one of the earliest occasions on which a peptide or protein hormone was developed into a widely used therapeutic treatment.

The clinical application of insulin to treat diabetes mellitus represented one of the first large-scale therapeutic uses of a peptide or protein hormone and remains one of the most consequential medical achievements of the twentieth century.

By the 1950s, peptide science had reached another landmark. In 1955, Frederick Sanger completed the first determination of the complete amino acid sequence of a protein, choosing insulin as his subject. 

Sanger’s work, for which he received the Nobel Prize in Chemistry in 1958, established that proteins and peptides have specific, reproducible amino-acid sequences.. 

This was foundational: it meant that peptides were not biological mysteries but molecules that could be understood, mapped, and eventually synthesised.

The same decade saw Vincent du Vigneaud achieve the first total chemical synthesis of a peptide hormone, oxytocin. 

The amino-acid sequence of oxytocin was reported in 1953, while its first total chemical synthesis was initially reported in 1953 and described fully in 1954.

Du Vigneaud demonstrated that a peptide could be constructed entirely in the laboratory, not merely extracted from biological material. He received the Nobel Prize in Chemistry in 1955. 

This was the proof of concept that opened the door to synthetic peptide research.

The Synthesis Revolution: 1960s and 1970s

One of the most significant technical developments in the entire history of peptides came in 1963, when Robert Bruce Merrifield introduced solid-phase peptide synthesis (SPPS).

The result was a technique that made peptide synthesis more systematic, reproducible and suitable for automation.

Researchers who had previously spent months attempting to synthesise a single peptide could now produce some sequences considerably more efficiently, although the difficulty and duration of synthesis continued to depend on the peptide’s length and chemical properties.

The ability to produce peptides reliably in the laboratory accelerated research across multiple fields simultaneously, from endocrinology to immunology to neuroscience.

The 1970s brought further refinement through the development of Fmoc (fluorenylmethyloxycarbonyl) chemistry. 

The Fmoc protecting group was introduced in 1970 and was subsequently adapted for use in solid-phase peptide synthesis during the later 1970s.

Fmoc chemistry allowed temporary protection to be removed under relatively mild basic conditions while other protecting groups remained in place. This made it an important alternative to earlier synthesis strategies.

Fmoc-based solid-phase peptide synthesis later became one of the principal methods used for routine synthetic peptide production, although it does not automatically guarantee improved yield or purity for every peptide sequence.

The Recombinant Era and Therapeutic Expansion: 1980s and 1990s

The 1980s brought a further transformation in how peptides could be produced. 

Recombinant DNA technology, which allows specific genetic sequences to be inserted into host organisms such as bacteria or yeast, enabled human-identical peptides to be produced at industrial scale. 

The first recombinant human insulin was approved by the US Food and Drug Administration (FDA) in 1982, replacing animal-derived insulin and establishing a new overarching framework for peptide-based therapeutics.

The significance of recombinant technology extended well beyond insulin. 

Human-identical peptides and proteins could now be manufactured with greater consistency and without depending entirely on extraction from animal or human tissues.

Recombinant manufacturing became especially important for larger peptides and proteins that were difficult or uneconomical to produce using chemical synthesis alone.

The 1990s expanded peptide research into oncology, with the development of radiolabelled peptides (peptides tagged with radioactive isotopes) for tumour imaging and targeted therapy. 

Somatostatin analogues, including octreotide derivatives, demonstrated that peptides could be engineered to target specific receptor types with a degree of precision that conventional small-molecule drugs could not achieve. 

This receptor specificity became one of the important advantages of some peptide-based compounds, although antibodies and carefully designed small-molecule drugs can also be highly selective.

The Peptide Engineering Era: 2000s and 2010s

Modern peptide engineering did not begin exclusively in the 2000s. Many of the techniques used today were first investigated considerably earlier.

Foundational research into PEGylation, the attachment of polyethylene glycol chains to proteins or peptides, began in the 1970s. The first PEGylated medicine was approved in 1990.

PEGylation can increase a molecule’s apparent size, reduce renal clearance and, in some cases, protect it from enzymatic breakdown.

Lipidation, the attachment of a fatty-acid or other lipid group, can encourage albumin binding, slow absorption or reduce the rate at which a peptide is cleared from circulation.

These modifications allowed compounds that might otherwise be broken down within minutes to remain active for hours, days, or even longer.

The Rise of GLP-1 Receptor Agonists

The first GLP-1 receptor agonist was approved in 2005. Longer-acting GLP-1 receptor agonists then became increasingly prominent during the 2010s.

GLP-1 is a naturally occurring peptide hormone involved in glucose regulation and appetite signalling.

It contributes to glucose-dependent insulin secretion, glucagon regulation, gastric emptying, appetite and food intake.

The development of structurally modified GLP-1 analogues with extended duration of action demonstrated how understanding a peptide’s natural mechanism could be combined with structural engineering to produce a compound with significantly enhanced clinical utility and altered pharmacokinetic properties.

Where Peptide Research Stands Today

Today, peptide science is understood not as the study of isolated molecules but as the study of signalling networks. 

Peptides are recognised as nodes within integrated regulatory systems that govern metabolism, immunity, tissue repair, cognitive function, and cellular ageing simultaneously. 

The shift from studying individual compounds to understanding how they interact within these networks represents the current frontier of the field.

This biology perspective is what gives modern Peptide Therapy research its depth. 

Curious About Peptide Research?

Understanding the history of peptide science helps make sense of where the research stands today and why certain compounds have attracted the scientific attention they have. 

If you are curious about Peptide Therapy research, you can schedule a consultation with one of our peptide specialists who can help you navigate the research and understand what is relevant to your interests.

Schedule a 1:1 consultation today

Frequently Asked Questions (FAQs)

When was peptide research first developed?

The modern scientific study of peptide hormones is often traced to 1902, when Bayliss and Starling identified secretin, widely regarded as the first hormone to be discovered. Their experiments demonstrated the concept of chemical messengers travelling through the bloodstream. Starling subsequently introduced the term “hormone” in 1905. The discovery and early clinical development of insulin in 1921 and 1922 became one of the earliest major therapeutic applications of a peptide or protein hormone. 

What is solid-phase peptide synthesis and why was it important?

Solid-phase peptide synthesis (SPPS), first reported by Robert Bruce Merrifield in 1963, is a method of building peptide chains step by step while anchored to a solid resin support. Before SPPS, synthesising peptides in the laboratory was technically demanding and time-consuming. Merrifield’s method made the process more systematic, reproducible and suitable for automation, transforming what researchers could study and enabling many peptides to be produced more efficiently and consistently than before.

What does bioidentical mean in Peptide Research?

In this context, the word “bioidentical” is generally used descriptively to mean that a peptide has the same amino-acid sequence and molecular structure as an endogenous peptide produced by the body. GHK is a naturally occurring copper-binding tripeptide found in human plasma, saliva and urine. When bound to copper, it forms the complex GHK-Cu. The bioidentical nature of these compounds is significant because structural identity may allow them to engage the same molecular targets as their endogenous counterparts.

How did technology change peptide production?

Recombinant DNA technology, developed in the 1970s and applied to peptide and protein production from the 1980s onward, allowed certain human peptides and proteins to be produced at industrial scale by inserting the relevant genetic sequence into host organisms such as bacteria or yeast. This provided an alternative to extracting biological molecules from human or animal tissues and enabled greater manufacturing consistency and scalability for suitable molecules. The first recombinant human insulin, approved by the FDA on 28 October 1982, was the landmark application of this technology and the first approved medicine produced using recombinant DNA technology.

Why is the history of peptides still important?

The compounds being studied in modern Peptide Therapy research are built on over a century of accumulated scientific understanding. The synthesis methods, quality standards, mechanistic frameworks, and research approaches used today are all products of the scientific milestones that preceded them. Understanding this history provides important context for evaluating the research behind individual compounds and appreciating the depth of the scientific foundation the field rests on.

Written by Elizabeth Sogeke, BSc Genetics, MPH

Elizabeth is a science and medical writer specialising in peptide science, longevity medicine, mitochondrial health, metabolic optimisation and regenerative health research. With a BSc in Genetics and a Master’s in Public Health, she combines a strong scientific foundation with experience translating complex biomedical research into clear, clinically informed education for the Peptide Therapy and longevity medicine space. Her work is centred on interpreting emerging peptide, metabolic and longevity research with scientific accuracy, clinical awareness and a clear understanding of how these therapies are being discussed and applied in modern health optimisation.